Value analysis of Danlou Xuanbi Tang in the treatment of stable angina pectoris with phlegm stasis syndrome in coronary heart disease
丹蒌宣痹汤治疗冠心病稳定型心绞痛痰瘀互结证的价值分析

摘要

目的 分析丹蒌宣痹汤治疗冠心病稳定型心绞痛痰瘀互结证的价值。方法 该研究对象为2022年5月至2024年5月到医院诊治的冠心病稳定型心绞痛痰瘀互结证患者，入选对象共92例，利用随机数字表法进行分组，分为对照组（常规西医治疗，n=46）与研究组（丹蒌宣痹汤治疗，n=46）。对比两组的治疗效果及血脂指标。结果 在临床疗效上，研究组显著高于对照组（P＜0.05）。在甘油三酯、总胆固醇及低密度脂蛋白胆固醇水平上，研究组均低于对照组（P＜0.05）。结论 丹蒌宣痹汤用于冠心病稳定型心绞痛痰瘀互结证患者的效果确切，有助于调节血脂指标的表达水平，提升临床疗效，临床可进一步推广应用。

Abstract

Objective To analyze the value of Danlou Xuanbi Tang in the treatment of stable angina pectoris with phlegm stasis syndrome in coronary heart disease.
Methods The study subjects were 92 patients with stable angina pectoris and phlegm stasis syndrome who received treatment at the hospital from May 2022 to May 2024. They were randomly divided into a control group (treated with conventional Western medicine, n=46) and a study group (treated with Danlou Xuanbi Tang, n=46) using a random number table method. Compare the treatment effects and blood lipid indicators between the two groups.
Results In terms of clinical efficacy, the study group was significantly higher than the control group (P<0.05). The levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in the study group were lower than those in the control group (P<0.05).
Conclusion   Danlou Xuanbi Tang has a definite effect on patients with stable angina pectoris and phlegm blood stasis syndrome in coronary heart disease. It helps regulate the expression level of blood lipid indicators, improve clinical efficacy, and can be further promoted and applied in clinical practice.